ClinicalTrials.gg
RecruitingNCT04970888ReCARDIOUpdated Dec 2, 2025

Comparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure

An interventional study of Cognitive training and Exercise training in Chronic Heart Failure and Aging, sponsored by Montreal Heart Institute. Recruiting at 1 site in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Primary conditionHeart FailureRegistry: Motor ActivityReclassifiedWhy we changed it
Registry
Motor Activity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Failure
Why
  1. Motor Activity is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Heart Failure.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Montreal Heart Institute · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Heart Failure by Montreal Heart Institute — 4 open to participants now, 4 under way, none of them phase 3. Heart Failure · Montreal Heart Institute.

Planned enrollment
3rd of 15
216 · median 120
Started
2021
with 2 others
No phase
8 of 22
2 open now
Registered
18th of 22
by date

Among the 22 studies in Heart Failure by Montreal Heart Institute, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 with no phase, and was the 18th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 22 studies in Heart Failure by Montreal Heart Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Failure by Montreal Heart Institute, or all of them as a file.
02

Study summary

The objective of this project is to assess the effects of combined physical exercise and cognitive training interventions on cognitive and brain health in patients with heart failure (HF). Also, the role of sex on the effects of the interventions will be assessed.

Read the detailed description

Cognitive impairment (CI) affects up to 50% of patients with heart failure (HF), and is associated with high mortality rates, poor quality of life, reduced functional capacities, and an overwhelming economic burden in Western countries. Non-pharmacological strategies could help enhance cognition in HF patients with CI. Combined physical exercise and cognitive training interventions have recently shown promising enhancement effects on cognition in patients with cardiovascular risk factors and mild cognitive impairment. The effects of combined interventions have never been tested in HF.

The main objective is to assess the effects of combined physical exercise and cognitive training interventions on cognition in patients with HF. Secondary objectives include: to characterize baseline and intervention-related changes in cerebral autoregulation, pulsatility and neurovascular coupling and to assess the role of sex on intervention effects.

Two-hundred and sixteen participants (36 men and 36 women/group) with stable HF regardless of aetiology and LVEF will take part in this study. All participants will have signed a written consent form before taking part in the study.

Patients will be stratified according to sex and LVEF (FEVG \< 40% et FEVG > 40%), and will be randomly assigned to one of the 3 following study arms: 1) Combined physical exercise and cognitive training; 2) Physical exercise alone; and 3) Usual medical care.

03

Conditions studied

  • Chronic Heart Failure
  • Aging

Browse trials for

Keywords

  • cognition
  • physical exercise
  • cognitive training
  • brain functions
  • combined intervention
  • heart failure
  • biomarkers
  • cerebral vasoreactivity
  • fitness
04

In context

Heart Failure Reclassified

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's planned enrollment of 216 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Montreal Heart Institute is the lead sponsor of 101 studies on the registry; 23 are open to participants now.

Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Motor Activity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years old
  • Stable chronic HF on maximally tolerated background treatment for at least 2 months (stable therapy with ACE-I, ARBs and MRA for at least 2 months), regardless of
  • with no limitation of physical activity in ordinary physical activity (i.e. class I), moderate symptoms (i.e. NYHA class II) or marked limitation in activity (i.e. NYHA class III)
  • Able to perform cognitive and physical training.

Exclusion criteria

Exclusion Criteria:

  • Acute cardiovascular event 1 month prior to randomization, including emergency visit or hospitalization for decompensated HF, acute myocardial infarction, stroke, and
  • Planned cardiovascular intervention within 6 months (implantation of any cardiac device, cardiac revascularization, heart transplantation)
  • Severe exercise intolerance
  • for exercise testing (e.g., uncorrected severe aortic or carotid stenosis, severe pulmonary hypertension, severe non-revascularizable coronary disease including left main coronary stenosis, significant myocardial ischemia or arrhythmia during low-intensity exercise, acute HF)
  • Severe respiratory disease
  • Non-cardiopulmonary limitation to exercise (e.g., arthritis, claudication or any peripheral neurological disease including other neurodegenerative diseases such as disabling Parkinson)
  • Uncontrolled diabetes or untreated thyroid dysfunction
  • Current or recent with \< 1 year
  • Chronic hemodialysis or peritoneal dialysis
  • Unable to read the form or unable to understand the oral explanations provided by the assessor.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    Combined

    Combined physical exercise and cognitive training. The combined intervention will include a cognitive training with aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform cognitive and exercise training sessions either home-based or centre-based.

    Other: Cognitive training · Other: Exercise training · Other: Usual care

  • Experimental
    Exercise

    The physical exercises intervention will include aerobic and resistance exercises training, three sessions per week for 6 months. Participants will be allowed to perform exercise training sessions either home-based or centre-based.

    Other: Exercise training · Other: Usual care

  • Active comparator
    Usual care

    Usual medical care with no interventions

    Other: Usual care

Interventions

  • OtherCognitive training

    The cognitive training will involve attention control training and memory training, with thrice-weekly 30-min sessions. Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.

  • OtherExercise training

    Participants will follow a 20-week physical training program, with 60-min thrice-weekly trainings. The training sessions will start with a 5-min warm-up, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with a 10-min cool-down. Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test. For home-training sessions, participants will have access to a complete exercise training program. A certified kinesiologist will supervise trainings. With the Heart rate sensor Polar H10, all the characteristics of the activities will be recorded (type of the activity, intensity, heart rate, duration). A kinesiologist will call participants every week to ensure the smooth running of the exercises training sessions and individualize the care according to the patient's level.

  • OtherUsual care

    All patients will receive usual care and be treated according to evidence-based treatments. This will include optimal medical therapy, systematic information regarding dietary and fluid management, and a recommendation for regular physical activity consistent with the latest update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Moreover, patients who benefit from a prescription for a cardiovascular rehabilitation program will be able to follow it, but they will not receive other forms of intervention for the duration of the study.

07

What researchers measure

Primary outcomes

  1. Change in general cognitive functioning

    Montreal Cognitive Assessment (0-30 score, with a higher score indicating a better cognitive functioning).

    Time frame: Baseline and post-intervention at 6 months

  2. Change in processing speed

    Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).

    Time frame: Baseline and post-intervention at 6 months

  3. Change in executive functions

    Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).

    Time frame: Baseline and post-intervention at 6 months

  4. Change in episodic memory

    Validated remote version of neuropsychological tests (Composite Z-score).

    Time frame: Baseline and post-intervention at 6 months

Secondary outcomes

  1. Change in cerebral autoregulation - frontal cortical region

    Variations of prefrontal cortical oxygen saturation (rSO2, \[HbO\]/(\[HbO\]+\[HbR\])) will be measured by Near Infrared Spectroscopy (NIRS), as a surrogate of cortical blood flow. Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of oxygen saturation measures and variations of peripheral blood pressure.

    Time frame: Baseline and post-intervention at 6 months

  2. Change in cerebral autoregulation - middle cerebral arteries

    Variations of cerebral blood flow velocity (cm/s) at the level of the middle cerebral artery will be measured by Transcranial Doppler (TCD). Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of cerebral blood flow measures and variations of peripheral blood pressure.

    Time frame: Baseline and post-intervention at 6 months

  3. Change in cerebral pulsatility - cortical frontal region

    Pulsatility will be measured as the normalized difference of relative near-infrared light intensity changes between systole and diastole, using NIRS in the prefrontal cortical region.

    Time frame: Baseline and post-intervention at 6 months

  4. Change in cerebral pulsatility - middle cerebral arteries

    Pulsatility will be measured as the normalized difference of relative blood flow velocities between systole and diastole, using TCD in the middle cerebral arteries

    Time frame: Baseline and post-intervention at 6 months

  5. Change in cerebral activity

    Significant changes in brain activity evoked by a Stroop task relative to baseline will be assessed by t-statistics maps, computed from variations of \[HbO\] and \[HbR\] measured by NIRS at the prefrontal cortex.

    Time frame: Baseline and post-intervention at 6 months

Other outcomes

  1. Change in cardiorespiratory fitness

    Maximum incremental cardiopulmonary exercise test (VO2 max (ml.kg.min)

    Time frame: Baseline and post-intervention at 6 months

  2. Change in 6-min walking test performance

    maximum distance performed in 6 minutes (distance, m)

    Time frame: Baseline and post-intervention at 6 months

  3. Change in upper limb muscle strength

    Grip strength test score (kg).

    Time frame: Baseline and post-intervention at 6 months

  4. Change in quality of life

    score on the 23 items of the Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: Baseline and post-intervention at 6 months

  5. Change in perceived self care behaviour

    European Heart Failure Self-care Behaviour Scale (EHFScB-9) will be completed. This self-reported questionnaire assesses the adherence to different self-care behaviours (e.g., eating low-salt diet, etc.).

    Time frame: Baseline and post-intervention at 6 months

  6. Change in anxiety

    State-Trait Anxiety Inventory questionnaire (Score ranges from 20-80, with a higher score indicating higher anxiety).

    Time frame: Baseline and post-intervention at 6 months

  7. Change in depressive symptoms

    Geriatric Depression Scale questionnaire (Score ranges from 0-30, with a higher score indicating larger depressive symptomatology).

    Time frame: Baseline and post-intervention at 6 months

  8. Change in sleep quality

    Pittsburgh Sleep Quality Index questionnaire (Score ranges from 0-21, with a higher score indicating worse sleep quality). symptomatology).

    Time frame: Baseline and post-intervention at 6 months

  9. Cognitive reserve

    Rami and colleagues' cognitive reserve questionnaire (Scale ranges from 0-26, with a higher score indicating a greater cognitive reserve).

    Time frame: Baseline

  10. Genotyping data

    genotyping data that include the APOE gene

    Time frame: baseline

  11. Change in NT-pro-BNP

    NT-pro-BNP (ng/L)

    Time frame: Baseline and post-intervention at 6 months

  12. Change in high-sensitive Troponin T

    hsTnT (ng/mL)

    Time frame: Baseline and post-intervention at 6 months

08

Study locations

1 of 1 sites recruiting
  • Preventive medicine and physical activity centre (centre EPIC), Montreal Heart Institute
    Montreal, Quebec H1T1N6, Canada
    Recruiting
    • Louis Bherer, PhD · Contactlouis.bherer@umontreal.ca · 514-374-1480
    • Louis Bherer, PhD · Principal investigator
    • Anil Nigam, MD · Sub investigator
    • Jean Rouleau, MD · Sub investigator
09

References and documents

Publications

  • Bherer L, Besnier F, Gagnon C, Vrinceanu T, Vincent T, Mohammadi H, Gauthier C, Duquesne C, Blanchette CA, Berube B, Said SN, Iglesies-Grau J, L'Allier P, Boulet J, Nigam A, Dionne V, Benhalima H, Dube MP, Duchesne S, Belleville S, Brassard P, Gagnon D, Lesage F, Gayda M, Soucy JP, Bouabdallaoui N, Liu-Ambrose T, Barha C, Poirier J, Eric Thorin, Vu M, Tournoux F, Vitali P, O'Meara E, Racine N, Rouleau JL. Investigating Physical Exercise and Cognitive Training Effects on Cognition and Brain Health in Men and Women with Heart Failure: The ReCARDIO Trial. CJC Open. 2026 Feb 26;8(6):637-645. doi: 10.1016/j.cjco.2026.02.014. eCollection 2026 Jun. PubMed 42327429 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 63 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2021
First posted
Jul 21, 2021
StartActual
Sep 1, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04970888
Collaborators
Canadian Institutes of Health Research (CIHR), The Montreal Health Innovations Coordinating Center (MHICC)
Responsible party
Louis Bherer (Associate scientific director, Direction of prevention, Montreal Heart Institute, Montreal Heart Institute) — Principal investigator
First posted
Jul 21, 2021
Start date
Sep 1, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Louis Bherer, PhD
Contact
louis.bherer@umontreal.ca
+1 514-374-1480 ext. 4355
Louis Bherer, PhD
principal investigator · Montreal Heart Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion